Discussing GI ASCO 2023 Highlights – practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.
August 24, 2024
Key Points
SPOTLIGHT – Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
NAPOLI3 – Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
MOUNTAINEER – FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
SUNLIGHT – Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer
Tags:
Related Posts
ConferencesWCLC2025ArticlesSeptember 18, 2025
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
ConferencesASCO2025July 31, 2025